Events

Horizon Europe info days - cluster 5 climate energy and mobility
MAY
Tue
06
09:00 - 19:00

This was 6 months ago

Location

online or Brussels

Charlemagne Building, Wetstraat 170, Brussel
Programmes
Climate, Energy, Mobility

The next calls of cluster 5 (climate, energy and mobility) will become public in early April. In order to inform all interested parties about these calls, the European Commission will organize a compact day of presentations on the 6th of May. The event will cover:

  • Insights into the policy context
  • in-depth discussion with the audience on the calls for proposals
  • a brokerage event to find partners for your envisaged projects 

You need to register before the 31st of March if you want to follow the event on-site but preferably you do this as soon as possible as places are limited. For online participation you also need to register but you can do this after the above-mentioned date. More information and the registration module can be found on the event webpage

Those who want to participate in the brokerage event are invited to register here. The deadline for this registration is the 11th of April.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.